2026 ICD-10-CM Diagnosis Code M33.22Polymyositis with myopathy

ICD-10-CM Codes›M00–M99›M30-M36›M33

ICD-10-CM M33.22
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

M33.22 is a billable ICD-10-CM diagnosis code for polymyositis with myopathy. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 545 through 547. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 115 closely related codes. Coders also document this condition as acute sarcoid polymyositis. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Systemic lupus erythematosus and connective tissue disorders.

For Medicare Advantage risk adjustment, M33.22 maps to CMS-HCC Category 93 (Rheumatoid Arthritis and Other Specified Inflammatory Rheumatic Disorders) under the V28 model, adding a risk factor of about 0.617 for a community, non-dual, aged beneficiary in payment year 2026.

Code Identity

ICD-10-CM Code
M33.22
Billable Status
Yes — Valid for Submission
Code Describes
Polymyositis with myopathy
Short Description
Polymyositis with myopathy
Same as the full description in the CMS dataset.
Parent Code
Polymyositis

Code Classification

ChapterM00–M99Diseases of the musculoskeletal system and connective tissue
SectionM30-M36Systemic connective tissue disorders
CategoryM33Dermatopolymyositis
This CodeM33.22Polymyositis with myopathy

Medicare Risk Adjustment (HCC)Billing

M33.22 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.

CMS-HCC V28 Category (Payment Model)
HCC 93— Rheumatoid Arthritis and Other Specified Inflammatory Rheumatic Disorders
Payment HCC · PY 2026 one of 508 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+0.617
community, non-dual, aged · ranges 0.288–0.617 across segments
Hierarchy
Supersedes HCC 94
less severe related categories are not paid alongside HCC 93
Prior Model (CMS-HCC V24)
HCC 40
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 40 · ESRD (V21): HCC 40 · ESRD (V21): HCC 75 · ESRD (V24): HCC 40
ESRD V21 weights: 0.072 dialysis, 0.274–0.398 functioning graft · ESRD V21 weights: 0.059 dialysis, 0.284–0.323 functioning graft · ESRD V24 weights: 0.058 dialysis, 0.284–0.414 functioning graft
Part D (RxHCC)
RxHCC 83 — Rheumatoid Arthritis and Other Inflammatory Polyarthropathy
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Acute sarcoid polymyositis
  • Myositis in sarcoidosis
  • Nodule in muscle
  • Polymyositis
  • Sarcoid myopathy

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR MUS024
Systemic lupus erythematosus and connective tissue disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Dermatomyositis

    a subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. the illness occurs with approximately equal frequency in children and adults. the skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. the disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. the childhood form of this disease tends to evolve into a systemic vasculitis. dermatomyositis may occur in association with malignant neoplasms. (from adams et al., principles of neurology, 6th ed, pp1405-6)
  • Polymyositis

    diseases characterized by inflammation involving multiple muscles. this may occur as an acute or chronic condition associated with medication toxicity (drug toxicity); connective tissue diseases; infections; malignant neoplasms; and other disorders. the term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. the illness may occur at any age, but is most frequent in the fourth to sixth decade of life. weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (adams et al., principles of neurology, 6th ed, pp1404-9)

Patient EducationClinical

Myositis

Myositis means inflammation of the muscles that you use to move your body. An injury, infection, or autoimmune disease can cause it. Two specific kinds are polymyositis and dermatomyositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert M33.22 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
710.4 Polymyositis
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
359.6 Infl myopathy in oth dis
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About M33.22Overview

What is the ICD-10 code for polymyositis with myopathy?

The ICD-10-CM code for polymyositis with myopathy is M33.22 (sometimes written as M3322). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Is M33.22 (Polymyositis) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report polymyositis with myopathy on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does M33.22 group to?

When polymyositis with myopathy is the principal diagnosis on an inpatient stay, it groups to MS-DRG 545, 546, 547, with relative weights from 0.8362 to 2.4817 depending on complications. Higher weights mean higher Medicare reimbursement.

Is M33.22 a CC or MCC?

CMS lists M33.22 as a CC (complication or comorbidity) for FY 2026. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 115 closely related codes in its exclusion list.

What is the ICD-9 equivalent of M33.22?

Under the General Equivalence Mappings, polymyositis with myopathy converts to ICD-9-CM 710.4 (polymyositis) and 359.6 (infl myopathy in oth dis). The mapping is approximate, so confirm the match fits the documentation.

What HCC is M33.22?

M33.22 (polymyositis with myopathy) maps to CMS-HCC Category 93 (Rheumatoid Arthritis and Other Specified Inflammatory Rheumatic Disorders), commonly written as HCC 93, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. It mapped to HCC 40 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 83.

Does M33.22 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, M33.22 adds a risk adjustment factor of about 0.617 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.288 to 0.617 depending on the payment segment). HCC 93 sits at the top of its hierarchy, so no other condition category supersedes it. See the full factor table on the HCC 93 category page.